Novo Nordisk received approval from the U.S. FDA for the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events. The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial program and the SELECT trial. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demo...